Rhino Biotech Limited
Rhino Biotech Limited (RBRXF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rbrxf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Shell Companies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Rhino Biotech LimitedYou RBRXF | $0M | N/A | — | — |
 Atlas Financial Holdings, Inc. AFHIF | $0M | N/A | — | -$0.44 |
 Amanasu Techno Holdings Corporation ANSU | $0M | N/A | — | -$0.00 |
 ConectiSys Corporation CONC | $1M | N/A | — | -$0.00 |
 Excellerant, Inc. EXCL | $0M | N/A | — | -$0.00 |
 Laredo Resources Corp. LRDR | $0M | N/A | — | -$2650.28 |
 Palayan Resources, Inc. PLYN | $0M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Rhino Biotech Limited (RBRXF) measures how much investors pay for each dollar of the company's trailing earnings. RBRXF's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
RBRXF pe ratio · 6 questionsRBRXF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via RBRXF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Rhino Biotech Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09